株式会社グローバルインフォメーション
TEL: 044-952-0102
表紙
市場調査レポート

間葉系幹細胞の世界市場

Mesenchymal Stem Cells

発行 Global Industry Analysts, Inc. 商品コード 297189
出版日 ページ情報 英文 167 Pages
納期: 即日から翌営業日
価格
本日の銀行送金レート: 1USD=112.85円で換算しております。

ご注意:Single user licenseはDRM(デジタル著作権管理システム)付PDFとなります。
PDFの閲覧には Adobe Digital Editions (無償)のインストールが必要となります。
認証されたPC上のみでの閲覧と、1回のプリントアウトが可能となっております。

Back to Top
間葉系幹細胞の世界市場 Mesenchymal Stem Cells
出版日: 2019年01月01日 ページ情報: 英文 167 Pages
概要

当レポートでは、間葉系幹細胞の世界市場について分析しております。また米国、カナダ、日本、欧州、アジア太平洋地域およびその他の地域の各地域についてそれぞれ包括的分析を提供すると共に、2009年から2018年までの各年ごとの見積りと予測をお伝え致します。さらに主要企業とニッチ企業を含む51社のプロファイルを交えつつ、概略下記内容でお届け致します。

第1章 序、調査方法および製品の定義

  • 調査の信頼性と報告の制約
  • 免責事項
  • データの解釈と報告レベル
  • 製品の定義と調査の範囲

第2章 エグゼクティブサマリー

  • 市場の概観
    • 間葉系幹細胞 - 医学における次の大きな飛躍
    • 現在および将来の分析
    • 間葉系幹細胞療法の現状と将来
    • 間葉系幹細胞治療:主なパイプライン製品のリスト(2013年12月現在)
    • 「既製」間葉系幹細胞の普及事業化が現実味を帯びる
    • ソフトウェア企業はこのブームで儲けようとしている
  • 市場促進要因、動向および課題
    • 人口の高齢化が間葉系幹細胞療法の需要を牽引
    • 胚性幹細胞研究についての議論が止まないのに対し、成体幹細胞療法は成長軌道に乗っている
    • 成体幹細胞および胚性幹細胞 - 比較
    • 間葉系幹細胞 対 胚または人工多能性幹細胞
    • 間葉系幹細胞療法は胚性幹細胞に適用される倫理問題の影響を受けない
    • 間葉系幹細胞 - 「標的化ドラッグデリバリー」に使える可能性のある運搬手段
    • 生体内特性に関連した抜け穴が療法の進歩を促す
    • 間葉系幹細胞市場に立ちはだかる大きな課題
  • 幹細胞市場 - マクロ的視点
    • 間葉系幹細胞が支配的
    • 幹細胞研究が急速に進んでいる
    • これまでの主な成果
    • 幹細胞研究分野における主な歴史的な出来事
    • 幹細胞研究を規制する法律 - 規制の概要
    • 主な国々における幹細胞研究に対する法規制
    • 市場のダイナミクスおよび動向
    • 北米が世界の幹細胞研究を支配
    • 幹細胞療法はコンセプトから現実に移り続ける
    • 幹細胞は医学における非常に大きな可能性の前兆となる
    • 長らく待たれている幹細胞療法に対する要請
    • 韓国が世界初の体性幹細胞ベースの治療を実施
    • 幹細胞市場に対する主な制約
    • 幹細胞ツーリズム- ブームか破滅のもとか?
    • 奇形腫 - もはや幹細胞治療の開発に対する障害ではない
    • 米国と日本が幹細胞特許で欧州に先行
    • 幹細胞治療の開発を抑制する課題
  • 主な幹細胞の変形の概況
    • 成体幹細胞
    • 低リスクの投資
    • 成体幹細胞は研究用投資をさらに集める
    • 多様性の低さ - 成体幹細胞の主な制約要因
    • 造血幹細胞 - 不朽の成功を収める
    • 制約要因
    • 人工多能性幹細胞 - ESCの代替
    • iPSの発見
    • 医薬品開発 - IPSの主なアプリケーション
    • 再生医療のためのiPSの使用
    • iPS細胞バンクの確立
    • 難治性および先天性疾患治療
    • 医学を変貌させる胚性幹細胞
    • 倫理問題や技術的なハードルがhESC研究を足踏みさせる
    • 安全性と有効性のデータの不足 - 主な懸念
  • アプリケーション別の間葉系幹細胞研究
    • 整形外科における間葉系幹細胞
    • 整形手術のための間葉系幹細胞ベースのモデル
    • 療法を必要とする領域への間葉系幹細胞の配布
    • 変形性関節症治療における間葉系幹細胞
    • 関節リウマチ治療における間葉系幹細胞
    • がん治療における間葉系幹細胞
    • 肝臓学における間葉系幹細胞
    • 神経学における間葉系幹細胞
    • 放射線治療における間葉系幹細胞
    • 糖尿病治療における間葉系幹細胞
    • 自己免疫疾患治療における間葉系幹細胞
    • 早発卵巣不全の治療における間葉系幹細胞
    • 遺伝子治療における間葉系幹細胞
    • 肺疾患治療における間葉系幹細胞
    • 結腸修復における間葉系幹細胞
    • 腎修復における間葉系幹細胞
  • 製品の概要
    • 間葉系幹細胞(MSC)- はじめに
    • 歴史
    • 同種間葉系幹細胞とは何か?
    • なぜ間葉系幹細胞はそんなに人気があるのか?
    • 間葉系幹細胞のいくつかの主な供給源
    • 骨髄
    • ウォートンのゼリーおよび臍帯血
    • 脂肪組織
    • 栄養膜組織
    • 羊水
    • 下顎智歯の歯芽を開発
    • 間葉系幹細胞治療のメカニズム
    • 間葉系幹細胞の重要な機能
    • 形態学
    • 識別/検出
    • 分化能
    • 免疫調節作用
    • 培養
    • 臨床用途
    • 臨床グレード間葉系幹細胞の生産
    • 間葉系幹細胞の欠点
  • 製品の革新と発売
    • Vitro Biopharma は一連の新しい幹細胞産製品を発表
    • Rainbow Scientific は Biological Industriesの幹細胞培養システムを発売
    • LABSは生物製剤スクリーニング用の新しいラボテストを発表
    • Vitro Diagnostics は一連の新製品を発表
    • IntelliCell BioSciences は非生物脂肪組織から間質血管画分細胞を開発
    • Vitro Diagnostics は細胞治療のための新製品を発表
    • Vitro Diagnostics は複数の幹細胞製品を発表
  • 最近の業界動向
    • Life TechnologiesはHarvard Universityとライセンスおよび幹細胞共同研究契約を締結
    • Stemedica Cell Technologies と Life Technologies は世界的な販売契約を締結
    • ThermoGenesis はThermoLineの資産をHelmer Scientificに売却
    • Athersysは虚血性脳卒中におけるMultiStem細胞療法の第2相臨床試験の拡大のためのMHRAの承認を受ける
    • Osiris Therapeutics はEMAからのProchymal®に対しオーファンドラッグ指定を受ける
    • 他31例
  • 主な企業
    • Aastrom Biosciences, Inc. (米国)
    • Cell Applications, Inc (米国)
    • Celprogen, Inc (米国)
    • Cyagen Biosciences Inc (米国)
    • EMD Millipore Corporation (米国)
    • 他15社
  • 世界市場展望

第3章 市場

  • 米国
  • カナダ
  • 日本
  • 欧州
  • アジア太平洋地域
  • その他の地域
目次
Product Code: MCP-7815

This report analyzes the worldwide markets for Mesenchymal Stem Cells in US$ Million. The report provides separate comprehensive analytics for the US, Canada, Japan, Europe, Asia-Pacific, and Rest of World. Annual estimates and forecasts are provided for the period 2015 through 2022. Also, a six-year historic analysis is provided for these markets. Market data and analytics are derived from primary and secondary research. Company profiles are primarily based on public domain information including company URLs. The report profiles 47 companies including many key and niche players such as -

Aastrom Biosciences, Inc.
Cell Applications, Inc.
Celprogen, Inc.
Cyagen US Inc.
Genlantis, Inc.
Lonza Group
Mesoblast Limited

Table of Contents

1. INTRODUCTION, METHODOLOGY & PRODUCT DEFINITIONS

  • Study Reliability and Reporting Limitations
  • Data Interpretation & Reporting Level
  • Quantitative Techniques & Analytics
  • Product Definitions and Scope of Study

2. MARKET OVERVIEW

  • Mesenchymal Stem Cells Market on a Rapid Growth Path
  • Current and Future Analysis
  • The Present and Future of MSC Therapies
  • Select MSC-based Therapeutics
  • Mesenchymal Stem Cell Research
    • Table 1: Mesenchymal Stem Cells-based (MSCs) Clinical Trials by Category (2018) (includes corresponding Graph/Chart)
  • Completed Phase III Studies with MSCs
  • MSCs are Being Explored for Several New Treatment Possibilities
  • Widespread Commercialization of 'Off-the-Shelf' MSCs to Become a Reality
  • Software Companies Endeavour to Cash in on the Boom

3. MARKET DRIVERS, TRENDS & ISSUES

  • Development of Regenerative Medicine Accelerates Demand for MSCs
    • Table 2: Global Regenerative Medicines Market by Category (2016): Percentage Breakdown for Biomaterials, Stem Cell Therapies and Tissue Engineering (includes corresponding Graph/Chart)
  • Ageing Demographics to Drive Demand for Mesenchymal Stem Cell Therapies
  • Global Aging Population Statistics - Opportunity Indicators
    • Table 3: Elderly Population (60+ Years) as a Percentage of Total Population (2017 & 2050) (includes corresponding Graph/Chart)
    • Table 4: Global Aging Population (2017 & 2050): Population of 60+ Individuals in '000s and as a Percentage of Total Population (includes corresponding Graph/Chart)
    • Table 5: Life Expectancy for Select Countries in Number of Years: 2018 (includes corresponding Graph/Chart)
  • Growing Prevalence of Chronic Diseases Propels Demand for Mesenchymal Stem Cells
  • Key Disease Statistics - Opportunity Indicators
    • Table 6: Worldwide Incidence of Cancer (2012, 2018 & 2040): Number of New Cases Diagnosed (includes corresponding Graph/Chart)
    • Table 7: World Cancer Incidence by Geographic Region and Gender (2018): Number of New Cancer Cases Reported (in Thousands) for Asia-Pacific, Europe, North America, Latin America & the Caribbean, and Africa (includes corresponding Graph/Chart)
    • Table 8: World Cancer Incidence by Cancer Type (2018): Number of New Cancer Cases Reported (in Thousands) for Breast, Cervix uteri, Colorectum, Liver, Lung, Oesophagus, Prostate, Stomach and Others (includes corresponding Graph/Chart)
    • Table 9: Fatalities by Heart Conditions - Estimated Percentage Breakdown for Cardiovascular Disease, Ischemic Heart Disease, Stroke, and Others (includes corresponding Graph/Chart)
    • Table 10: Global Annual Medical Cost of CVD in US$ Billion (2010-2030) (includes corresponding Graph/Chart)
  • Growing Volume of Orthopedic Procedures: An Opportunity for the MSC Market
    • Table 11: Global Orthopedic Market by Segment (2018): Percentage Breakdown of Value Sales for Arthroscopy / Soft Tissue, Extremities, Hips, Knees, Orthobiologics, Spine, Trauma and Others (includes corresponding Graph/Chart)
  • Adult Stem Cell Therapies on Growth Trajectory, as Controversies Continue to Haunt Embryonic Stem Cell Research
  • Adult Stem Cells and Embryonic Stem Cells - A Comparison
  • MSCs Versus Embryonic or Induced Pluripotent Stem Cells
  • MSC Therapies - Immune to Ethical Issues Applicable to Embryonic Stem Cells
  • MSCs - A Potential Vehicle for 'Targeted Drug Delivery'
  • Stem Cell Based Bone Grafts: Promising Growth Ahead
  • Loopholes Associated with In Vivo Properties Constrain Therapeutic Advancements
  • Major Challenges Confronting Mesenchymal Stem Cell Market
  • Allogeneic MSCs - Offering Promise in Immunosuppressive and Tissue Repair Therapy
  • Administration Route Determines the Effectiveness of MSCs

4. REVIEW OF SELECT MAJOR STEM CELL VARIANTS

  • Adult Stem Cells
  • A Low Risk Investment
  • Adult Stem Cells Garner More Investments for Research
  • Low Versatility - A Major Limiting Factor for Adult Stem Cells
  • Hematopoietic Stem Cells - Enjoying Enduring Success
  • Restraining Factors
  • Induced Pluripotent Stem Cells - An Alternative to ESCs
  • A Peek into the Discovery of iPS
  • Drug Development - A Major Application for iPS
  • Use of iPS for Regenerative Medicine
  • Establishing iPS Cell Banks
  • Intractable and Congenital Disease Treatments
  • Embryonic Stem Cells to Transfigure Medicine
  • Ethical Issues and Technical Hurdles Bog Down hESC Research
  • Lack of Safety and Efficacy Data - A Key Concern

5. MESENCHYMAL STEM CELL RESEARCH BY APPLICATION

  • Mesenchymal Stem Cells in Orthopedics
  • MSC based Models for Orthopedic Repair
  • Delivery of MSCs to Regions Requiring Therapy
  • MSCs in the Treatment of Osteoarthritis
  • MSCs in the Treatment of Rheumatoid Arthritis
  • MSCs in Cancer Treatment
  • MSCs in Hepatology
  • MSCs in Neurology
  • MSCs in Cardiology
  • MSCs in Radiotherapy
  • MSCs in the Treatment of Diabetes
  • MSCs in the Treatment of Autoimmune Diseases
  • MSCs in Treatment of Premature Ovarian Failure
  • MSCs for Gene Therapy
  • MSC Therapy in the Treatment of Lung Diseases
  • MSCs for Treating Liver Disease
  • MSCs for Treating Multiple Sclerosis-Phase II Clinical Trial Completed in the US (2016)
  • MSCs in Colon Repair
  • MSCs in Kidney Repair

6. PRODUCT OVERVIEW

  • Mesenchymal Stem Cells (MSCs) - An Introduction
  • History
  • What Are Allogeneic Mesenchymal Stem Cells?
  • Some Major Sources of Mesenchymal Stem Cells
  • Bone Marrow
  • Wharton's Jelly and Umbilical Cord Blood
  • Adipose Tissue
  • Trophoblastic Tissues
  • Amniotic Fluid
  • Developing Tooth Bud of Mandibular Third Molar
  • Mechanism of Mesenchymal Stem Cell Therapy
  • Important Features of Mesenchymal Stem Cells
  • Morphology
  • Identification/Detection
  • Differentiation Capacity
  • Immuno-modulatory Effects
  • Culturing
  • Clinical Use
  • Production of Clinical-Grade MSCs
  • Drawbacks of MSCs

7. COMPETITIVE LANDSCAPE

  • 7.1 Focus on Select Players
  • Cell Applications, Inc. (USA)
  • Celprogen, Inc. (USA)
  • Cyagen US Inc. (USA)
  • Genlantis, Inc. (USA)
  • Lonza Group (Switzerland)
  • Mesoblast Limited (Australia)
  • MilliporeSigma (USA)
  • Neuromics (USA)
  • Orthofix International N.V. (Italy)
  • PromoCell GmbH (Germany)
  • R&D Systems, Inc. (USA)
  • ScienCell Research Laboratories (USA)
  • Stemcell Technologies Inc. (Canada)
  • Stemedica Cell Technologies, Inc. (USA)
  • Thermo Fischer Scientific, Inc. (USA)
  • Vitro Biopharma (USA)
  • 7.2 Product Launches
  • RoosterBio Launches CliniControl(tm) (CC) Product Portfolio
  • Provia Labs Launches Library of Stem Cell Material Available for Researchers
  • JCR Pharmaceuticals Develops TEMCELL HS
  • PuRec Announces Plans to Produce MSCs/RECs
  • 7.3 Recent Industry Activity
  • Mesoblast Partners with Tasly for MPC Products
  • SanBio Acquires Patent Portfolio Regarding Cell Medicines Derived from MSC
  • Otsuka to Acquire New Shares Issued by TWO CELLS
  • Stemedica Receives FDA Approval for Phase Iia Clinical Study for Traumatic Brain Injury
  • Stemedica Enrolls into Phase I/IIa Clinical Study for Ischemic Stroke

8. GLOBAL MARKET PERSPECTIVE

    • Table 12: World Recent Past, Current and Future Analysis for Mesenchymal Stem Cells by Geographic Region - US, Canada, Japan, Europe, Asia-Pacific (excluding Japan), and Rest of World Markets Independently Analyzed with Annual Revenue Figures in US$ Million for Years 2015 Through 2022 (includes corresponding Graph/Chart)
    • Table 13: World Historic Review for Mesenchymal Stem Cells by Geographic Region - US, Canada, Japan, Europe, Asia-Pacific (excluding Japan), and Rest of World Markets Independently Analyzed with Annual Revenue Figures in US$ Million for Years 2009 Through 2014 (includes corresponding Graph/Chart)
    • Table 14: World 14-Year Perspective for Mesenchymal Stem Cells by Geographic Region - Percentage Breakdown of Annual Revenues for US, Canada, Japan, Europe, Asia-Pacific (excluding Japan), and Rest of World Markets for Years 2009, 2018 & 2022 (includes corresponding Graph/Chart)

9. REGIONAL MARKET PERSPECTIVE

  • 9.1 The United States
  • A. Market Analysis
    • Rapidly Ageing Population: A Major Driving Demand for MSC based Therapies
    • Table 15: The US Elderly Population by Age Group in Million (2016-2050) (includes corresponding Graph/Chart)
    • Increasing Incidence of Chronic Diseases Drives Focus onto MSCs
    • Table 16: CVD in the US: Cardiovascular Disease Prevalence in Adults by Gender & Age Group (includes corresponding Graph/Chart)
    • Table 17: New Cancer Cases in Males in US by Body Site (2018) (includes corresponding Graph/Chart)
    • Table 18: New Cancer Cases in Females in US by Body Site (2018) (includes corresponding Graph/Chart)
    • Arthritis
    • Table 19: % of Population Diagnosed with Arthritis by Age Group (includes corresponding Graph/Chart)
    • Prochymal Obtains Fast Track Designation from FDA
    • MSCs for Treating Multiple Sclerosis-Phase II Clinical Trial Completed in the US
    • Rising Governmental Investments in Stem Cell Therapies - A Growth Booster
    • FDA Issues Warning Against Illegal Stem Cell Therapies
    • US Regulates Stem Cells as Drugs
    • Federal Law on Stem Cells in the US
    • NIH at the Forefront of Research Funding
    • NIH Guidelines on Stem Cell Research Funding
    • Bans and Restrictions on Stem Cell Research
    • American Type Culture Collection Inc (ATCC) - A Major Non-Profit Organization
  • B. Market Analytics
    • Table 20: The US Recent Past, Current and Future Analysis for Mesenchymal Stem Cells Analyzed with Annual Revenue Figures in US$ Million for Years 2015 through 2022 (includes corresponding Graph/Chart)
    • Table 21: The US Historic Review for Mesenchymal Stem Cells Analyzed with Annual Revenue Figures in US$ Million for Years 2009 through 2014 (includes corresponding Graph/Chart)
  • 9.2 Canada
  • A. Market Analysis
    • Current and Future Analysis
    • Prochymal - Canada's First MSC-based Therapy
  • B. Market Analytics
    • Table 22: Canadian Recent Past, Current and Future Analysis for Mesenchymal Stem Cells Analyzed with Annual Revenue Figures in US$ Million for Years 2015 through 2022 (includes corresponding Graph/Chart)
    • Table 23: Canadian Historic Review for Mesenchymal Stem Cells Analyzed with Annual Revenue Figures in US$ Million for Years 2009 through 2014 (includes corresponding Graph/Chart)
  • 9.3 Japan
  • A. Market Analysis
    • Current and Future Analysis
    • Increasing Demand for Regenerative Medicine in Geriatric Healthcare and Cancer Care to Drive Demand for Mesenchymal Stem Cells
    • Table 24: Japanese Population by Age Group (2015 & 2040): Percentage Share Breakdown of Population for 0-14, 15-64 and 65 & Above Age Groups (includes corresponding Graph/Chart)
    • Table 25: Cancer Related Incidence and Deaths by Site in Japan: 2018 (includes corresponding Graph/Chart)
    • New Regulation for Accelerated Stem Cell Approval and Its Impact on Stem Cells Product Market
  • B. Market Analytics
    • Table 26: Japanese Recent Past, Current and Future Analysis for Mesenchymal Stem Cells Analyzed with Annual Revenue Figures in US$ Million for Years 2015 through 2022 (includes corresponding Graph/Chart)
    • Table 27: Japanese Historic Review for Mesenchymal Stem Cells Analyzed with Annual Revenue Figures in US$ Million for Years 2009 through 2014 (includes corresponding Graph/Chart)
  • 9.4 Europe
  • A. Market Analysis
    • Current and Future Analysis
    • Ageing Population to Drive Demand for MSC based Therapies
    • Table 28: European Population by Age Group (2016, 2030 & 2050): Percentage Share Breakdown by Age Group for 0-14, 15-64, and 65 & Above (includes corresponding Graph/Chart)
    • Table 29: European Country-wise Statistics of 65+ Population as % of Total Population: 2018 & 2030 (includes corresponding Graph/Chart)
    • Cancer in Europe: Key Statistics
    • Table 30: Cancer Related Incidence and Deaths by Site in Europe: 2018 (includes corresponding Graph/Chart)
    • Legislations on Stem Cell Research and Therapy in the EU
    • Unproven Stem Cell Therapies Receive Government Backing in the EU?
    • Scientists and Government Tussle over Safety of Stamina Foundation's MSC Therapy in Italy
    • Stem Cell Clinics Shut Down in Germany due to Malpractices
  • B. Market Analytics
    • Table 31: European Recent Past, Current and Future Analysis for Mesenchymal Stem Cells Analyzed with Annual Revenue Figures in US$ Million for Years 2015 through 2022 (includes corresponding Graph/Chart)
    • Table 32: European Historic Review for Mesenchymal Stem Cells Analyzed with Annual Revenue Figures in US$ Million for Years 2009 through 2014 (includes corresponding Graph/Chart)
  • 9.5 Asia-Pacific
  • A. Market Analysis
    • Current and Future Analysis
    • Overview of Select Countries
      • Australia
      • Stem Cell Tourism - A Popular Trend in Australia
      • South Korea
      • South Korea Pacing towards Regaining Lost Glory in Stem Cell Research
      • South Korea Upbeat on Stem Cell Therapy Market Potential
      • India
      • An Outline of the Stem Cell Research Structure in India
      • A Regulatory Picture of the Indian Stem Cell Research and Therapy
      • Adult Stem Cells - A Highly Money-Spinning Market
      • Indians 'Bank' on Dental Stem Cells
      • New Zealand
      • Stem Cell Research Scenario in New Zealand
  • B. Market Analytics
    • Table 33: Asia-Pacific Recent Past, Current and Future Analysis for Mesenchymal Stem Cells Analyzed with Annual Revenue Figures in US$ Million for Years 2015 through 2022 (includes corresponding Graph/Chart)
    • Table 34: Asia-Pacific Historic Review for Mesenchymal Stem Cells Analyzed with Annual Revenue Figures in US$ Million for Years 2009 through 2014 (includes corresponding Graph/Chart)
  • 9.6 Rest of World
  • A. Market Analysis
    • Current and Future Analysis
    • Stem Cell Research in Full Swing in Israel
  • B. Market Analytics
    • Table 35: Rest of World Recent Past, Current and Future Analysis for Mesenchymal Stem Cells Analyzed with Annual Revenue Figures in US$ Million for Years 2015 through 2022 (includes corresponding Graph/Chart)
    • Table 36: Rest of World Historic Review for Mesenchymal Stem Cells Analyzed with Annual Revenue Figures in US$ Million for Years 2009 through 2014 (includes corresponding Graph/Chart)

10. COMPANY PROFILES

  • Total Companies Profiled: 47 The United States (25) Canada (1) Japan (2) Europe (6) - Germany (2) - The United Kingdom (1) - Rest of Europe (3) Asia-Pacific (Excluding Japan) (9) Latin America (1) Middle East (3)
Back to Top